Experimental Nutrient Kit May Avert Postpartum Depression

This article originally appeared here.
Share this content:
Experimental Nutrient Kit May Avert Postpartum Depression
Experimental Nutrient Kit May Avert Postpartum Depression

TUESDAY, March 14, 2017 (HealthDay News) -- Researchers suggest that three days of an experimental dietary supplementation may eliminate depressed mood after childbirth, according to a study published online March 13 in the Proceedings of the National Academy of Sciences.

Jeffrey Meyer, M.D., Ph.D., a professor of psychiatry at the University of Toronto and co-creator of the product, and colleagues developed a dietary kit to be taken in the first three to five days after childbirth. The ingredients included blueberry juice and blueberry extract and the amino acids tryptophan and tyrosine. To test the product, the researchers assigned 21 healthy new mothers to receive the supplementation for three days, and compared them with 20 new mothers in the control group. The mothers' average age was 32 years.

The researchers found that on day five after childbirth -- when sadness tends to peak -- those who took the supplements scored better on tests of mood. Also, women in the control group showed "robust" signs of depressed mood, while those in the supplement group did not.

"This dietary supplement designed to counter functions of elevated monoamine oxidase activity eliminates vulnerability to depressed mood during the peak of postpartum blues," the authors write.

Meyer is developing natural health products to treat high-risk states for major depressive episode, and is listed as the inventor on a patent application for this dietary supplement.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »